First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-3404
Full Text
Open PDFAbstract
Available in full text
Date
June 11, 2013
Authors
Publisher
American Association for Cancer Research (AACR)